Orthopedic medicines firm Anika Therapeutics has secured CE mark for a treatment indicated to relieve pain and restore function in tendons damaged by chronic lateral epicondylosis.

The Orthovisc-T has been designed to offer lubrication to the site of the damaged tendons to advance tendon gliding, in addition to supporting tendon repair.

It can be administered through injection into the site of injury to relieve pain and restore function of tendons damaged by chronic injury and overuse.

It includes biocompatible, non-animal-derived and non-inflammatory formulation of hyaluronic acid, which is similar that can be observed in Orthovisc and Monovisc.

Anika also produces Hyalofast, which is a biodegradable, hyaluronic acid-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects.

Both Hyalofast and Orthovisc-T have not yet received approval in the US.

Anika Therapeutics president and CEO Dr Charles Sherwood said: "We're excited to announce the timely European approval of Orthovisc-T for the treatment of pain associated with one of the most common overuse injuries to connective tissues, the condition commonly described as tennis elbow.

"The availability of Orthovisc-T not only promises to help millions of people in Europe find relief from this painful condition, it also expands our global foothold in orthopedic medicine and provides real-world clinical experience to inform our path towards regulatory submission in the U.S."